Why Ovarian Cancer Is So Hard to Catch Early

Ovarian cancer has long carried a difficult reputation — not because it is untreatable, but because it is so frequently found late. Understanding why that happens requires looking at both biology and the current limits of diagnostic medicine.

The ovaries sit deep within the pelvis, surrounded by other organs. A growing tumor in this location can reach a meaningful size before it presses on surrounding tissue enough to cause noticeable discomfort. By the time symptoms do emerge, they tend to be subtle and nonspecific: bloating, mild pelvic pressure, changes in appetite, or an increased urge to urinate. These symptoms are common to many far less serious conditions, which means women — and sometimes clinicians — may attribute them to digestive issues, menopause-related changes, or aging in general.

According to the American Cancer Society, roughly 80% of ovarian cancers are diagnosed at stage III or IV, when the cancer has spread beyond the ovary to the abdomen, lymph nodes, or other organs. Five-year survival rates differ sharply between early and late-stage diagnosis, underscoring why earlier detection matters. This pattern shares a troubling similarity with pancreatic cancer's detection challenges, where vague early symptoms also delay diagnosis.

Symptoms Worth Taking Seriously

The Ovarian Cancer Research Alliance and other clinical bodies suggest that women who experience bloating, pelvic or abdominal pain, difficulty eating or feeling full quickly, or urinary urgency on most days over a period of two to three weeks should contact their healthcare provider. The concern is not any single symptom but their persistence and combined frequency. This guidance applies especially to postmenopausal women, for whom new abdominal or pelvic symptoms are less likely to have a hormonal explanation.

The Screening Gap: Why No Routine Test Exists

One of the most important facts about ovarian cancer is that, unlike breast or cervical cancer, there is currently no recommended routine screening test for women at average risk. Two tools have been widely studied — the CA-125 blood test and transvaginal ultrasound — but large clinical trials have not shown that using them for general population screening reduces deaths from ovarian cancer. More concerning, both tests produce a high rate of false positives, leading to unnecessary surgeries and anxiety in women who turn out not to have cancer.

The CA-125 blood test measures a protein that can be elevated in ovarian cancer, but it is also raised by endometriosis, uterine fibroids, pelvic inflammatory disease, and even normal menstruation. This lack of specificity makes it unreliable as a first-line screen in asymptomatic women. Similarly, transvaginal ultrasound can detect ovarian masses but cannot reliably distinguish between benign cysts — which are extremely common — and malignant tumors.

Research into improved biomarkers and multi-modal screening approaches continues, but as of current evidence, no combination test has cleared the bar for widespread clinical recommendation in average-risk individuals.

~80%

Ovarian cancer cases diagnosed at late stage

According to the American Cancer Society, approximately 80% of ovarian cancers are not detected until stage III or IV, when the disease has spread beyond the ovary.

35–46%

Lifetime risk for BRCA1 mutation carriers

Research published in peer-reviewed oncology literature estimates that women with BRCA1 mutations face a lifetime ovarian cancer risk of 35–46%, compared to roughly 1–2% in the general population.

~19,000

New ovarian cancer diagnoses per year in the US

The American Cancer Society estimates approximately 19,000 women are diagnosed with ovarian cancer annually in the United States, making it the fifth leading cause of cancer death among women.

Risk Factors and Who Should Consider Closer Monitoring

While routine screening is not recommended for the general population, women with certain risk factors may benefit from a different approach, guided by their healthcare provider.

The most significant risk factor is a hereditary gene mutation, particularly in BRCA1 or BRCA2. Women with a BRCA1 mutation face a lifetime ovarian cancer risk estimated between 35% and 46%, compared to roughly 1–2% in the general population. BRCA2 mutations carry a somewhat lower but still substantially elevated risk. Lynch syndrome — a hereditary condition affecting DNA mismatch repair — also raises ovarian cancer risk alongside colorectal and endometrial cancers.

Other risk factors include:

  • Age — most diagnoses occur after menopause, with peak incidence in the late 60s to early 70s
  • A personal or family history of ovarian, breast, or colorectal cancer
  • Never having been pregnant (nulliparity)
  • Endometriosis, particularly the endometrioid and clear cell subtypes

By contrast, factors associated with a reduced risk include oral contraceptive use, pregnancy, and breastfeeding — all of which suppress ovulation. For a related look at how reproductive hormone cycles connect to ovarian health, see what ovulation actually is and why it matters.

Women with known BRCA mutations or strong family histories should speak with their provider or a genetic counselor about personalized surveillance strategies, which may include more frequent pelvic exams, CA-125 monitoring, or discussion of risk-reducing surgery.

Know Your Family History Before Your Appointment

Before speaking with your doctor about ovarian cancer risk, compile a basic family health history — noting any relatives diagnosed with ovarian, breast, colorectal, or uterine cancers, along with the age at diagnosis. This information helps your provider assess whether hereditary risk factors may be present and whether genetic counseling is appropriate. A three-generation family history is considered the most informative.

What Research Is Showing and What It Means for Patients

Researchers continue to pursue better early detection methods. Several promising directions are under investigation, including liquid biopsy techniques — blood tests that detect fragments of tumor DNA circulating in the bloodstream — and more precise protein biomarker panels that could differentiate ovarian cancer from benign pelvic conditions more reliably than CA-125 alone.

The United Kingdom's UKCTOCS trial, one of the largest ovarian cancer screening studies ever conducted, examined a multimodal strategy combining CA-125 trends over time with ultrasound. While the trial showed some ability to detect cancers at earlier stages, it ultimately did not demonstrate a statistically significant reduction in ovarian cancer deaths across the full study population. These findings reinforce that even well-designed screening approaches face fundamental biological obstacles with this disease.

Genetic risk assessment is one area where meaningful clinical progress has occurred. Broader population-level BRCA testing is now recommended by several professional organizations for women with breast cancer, and guidelines for hereditary cancer risk evaluation continue to evolve. For older women concerned about a family pattern of cancer, discussing genetic counseling with a provider is a reasonable and increasingly accessible step.

For context on how detection challenges compare across gynecologic and other cancers, it may help to read about breast cancer screening considerations after 60, where established tools like mammography have a different evidence profile.

“The greatest obstacle in ovarian cancer is not the disease itself — it is the silence of its early stages. Until we have a validated screening tool, symptom awareness remains one of the most powerful tools available to patients.”

— Deborah Armstrong, Gynecologic oncologist and ovarian cancer researcher, Johns Hopkins Medicine

This article is for general informational and educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional regarding any symptoms, personal health concerns, or medical decisions.